ATLAS Phase III Data Point Avastin/Tarceva Combo In Positive Direction
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Phase III results using an Avastin and Tarceva combination in non-small cell lung cancer could mean FDA will not insist on survival data before approving Tarceva's supplemental NDA in first-line maintenance non-small cell lung cancer. Genentech disclosed results from the ATLAS trial Feb. 2
You may also be interested in...
Tarceva Advisory Committee To Focus On Treatment Alternatives, Subgroup Concerns
ODAC will review currently available treatment options and negative treatment effects in subgroups as OSI seeks to expand Tarceva's indication to first-line maintenance and monotherapy in NSCLC.
Tarceva Advisory Committee To Focus On Treatment Alternatives, Subgroup Concerns
ODAC will review currently available treatment options and negative treatment effects in subgroups as OSI seeks to expand Tarceva's indication to first-line maintenance and monotherapy in NSCLC.
Roche Ups Negotiating Ante With Hostile Bid For Genentech
By making a hostile bid for Genentech at a lower price, Roche is trying to address at least two important concerns in one blow: uncertainty over upcoming results of a key clinical trial for the blockbuster Avastin cancer medication and offsetting potentially higher financing costs needed to ink the deal due to the troubled economic climate